14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 6 May 2024

Trading levels for NVAX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.87 3.40 %
R2 4.80 1.98 %
R1 4.76 1.10 %
Current price: 4.71
Support S1 4.63 -1.74 %
S2 4.59 -2.61 %
S3 4.52 -4.03 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.29 12.31 %
R2 4.94 4.88 %
R1 4.88 3.61 %
Current price 4.71
Support S1 4.41 -6.37%
S2 4.30 -8.70%
S3 4.15 -11.89%

NVAX Predictions History

3 years ago
JS predicted that NVAX for 2021-03-23 is going $242.79 (10.44%)

3 years ago
rajsan2014.221588 predicted that NVAX for 2021-03-23 is going

Rank:

3 years ago
JS predicted that NVAX for 2021-03-17 is going $218.99 (-2.87%)

3 years ago
rajsan2014.221588 predicted that NVAX for 2021-03-17 is going $230.00 (2.01%)

Rank:

3 years ago
jjsheets330 predicted that NVAX for 2021-03-15 is going $307.00 (51.40%)

3 years ago
mylesb predicted that NVAX for 2021-03-15 is going $230.00 (13.43%)

Rank:

3 years ago
JS predicted that NVAX for 2021-03-12 is going $200.48 (-1.13%)

3 years ago
SHAMOO predicted that NVAX for 2021-03-12 is going

3 years ago
Moe A predicted that NVAX for 2021-03-12 is going $237.50 (17.13%)

Rank:

3 years ago
jjsheets330 predicted that NVAX for 2021-03-12 is going $285.00 (51.89%)

Click to get the best stock tips daily for free!

About Novavax Inc

Novavax Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria... NVAX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT